Progress and Prospects of Interleukin-22 in the Treatment of Non-alcoholic Fatty Liver Disease
DOI:
https://doi.org/10.53469/jcmp.2025.07(01).19Keywords:
Non-alcoholic fatty liver disease, IL-22Abstract
Non-alcoholic fatty liver disease (NAFLD), also known as metabolism-associated fatty liver disease (MAFLD), has turned into the most prevalent chronic liver disease all over the world, with a complex pathogenesis and a lack of specific therapeutic agents. Interleukin-22 (IL-22), as a cytokine, plays a crucial role in liver physiology and pathology. The aim of this paper is to review the prospects and outlook of interleukin-22 (IL - 22) in the treatment of NAFLD, introduce the biological functions of IL - 22, discuss its mechanism of action in NAFLD, including its regulatory effects on liver inflammation, liver fibrosis, and lipid metabolism, etc., and analyse the current research advances on the treatment of NAFLD based on IL - 22, the challenges it faces, and the possible directions for future development.
References
Chinese Medical Association Hepatology Section. Guidelines for the prevention and treatment of metabolism-related (non-alcoholic) fatty liver disease (2024 edition). Chinese Journal of Liver Diseases, 2024, 32(05):418-434. DOI:10.3760/cma.j.cn501113-20240327-00163
Zhou J, Zhou F, Wang W, et al. Epidemiological features of NAFLD from 1999 to 2018 in China[J]. Hepatology, 2020, 71(5): 1851-1864. DOI: 10.1002/ hep.31150.
Nagem RA, Colau D, Dumoutier L, Renauld JC, Ogata C, Polikarpov I. Crystal structure of recombinant human interleukin-22. structure. 2002 Aug;10(8) :1051-62. doi: 10.1016/s0969-2126(02)00797-9. PMID: 12176383.
Dudakov JA, Hanash AM, van den Brink MR. Interleukin-22: immunobiology and pathology. Annu Rev Immunol. 2015;33:747-85. doi: 10.1146/annurev- immunol-032414-112123. epub 2015 Feb 11. PMID: 25706098; PMCID: PMC4407497.
Dumoutier L, Van Roost E, Ameye G, Michaux L, Renauld JC. IL-TIF/IL-22: genomic organisation and mapping of the human and mouse genes. Genes Immun. 2000 Dec;1(8):488-94. doi: 10.1038/sj.gene.6363716. PMID: 11197690.
Rutz S, Ouyang W. Regulation of interleukin-10 and interleukin-22 expression in T helper cells. Curr Opin Immunol. 2011 Oct; 23(5): 605-12. doi: 10.1016/ j.coi.2011.07.018. Epub 2011 Aug 20. PMID: 21862302.
Rutz S, Eidenschenk C, Ouyang W. IL-22, not simply a Th17 cytokine. Immunol Rev. 2013 Mar;252(1):116-32. doi: 10.1111/imr.12027. PMID: 23405899.
Ouyang W, O'Garra A. IL-10 Family Cytokines IL-10 and IL-22: from Basic Science to Clinical Translation. Immunity. 2019 Apr 16;50(4):871-891. doi: 10.1016/j.immuni.2019.03.020. pmid: 30995504.
Xie MH, Aggarwal S, Ho WH, Foster J, Zhang Z, Stinson J, Wood WI, Goddard AD, Gurney AL. Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R. J Biol Chem. 2000 Oct 6;275(40):31335-9. doi: 10.1074/jbc.M005304200. PMID: 10875937.
Kotenko SV, Izotova LS, Mirochnitchenko OV, Esterova E, Dickensheets H, Donnelly RP, Pestka S. Identification of the functional interleukin-22 ( IL-22) receptor complex: the IL-10R2 chain (IL-10Rbeta ) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL IL-10R2 chain (IL-10Rbeta ) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes. J Biol Chem. 2001 Jan 26;276(4):2725-32. doi: 10.1074/jbc.M007837200. Epub 2000 Oct 16. PMID: 11035029.
Lejeune D, Dumoutier L, Constantinescu S, Kruijer W, Schuringa JJ, Renauld JC. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J Biol Chem. 2002 Sep 13;277(37):33676-82. doi: 10.1074/jbc.jp. 10.1074/jbc.M204204200. Epub 2002 Jun 26. PMID: 12087100.
Mitra A, Raychaudhuri SK, Raychaudhuri SP. IL-22 induced cell proliferation is regulated by PI3K/Akt/mTOR signaling cascade. Cytokine. 2012 Oct;. 60(1):38-42. doi: 10.1016/j.cyto.2012.06.316. Epub 2012 Jul 25. PMID: 22840496.
Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018 Jul;24(7). 908-922. doi: 10.1038/s41591-018-0104-9. Epub 2018 Jul 2. PMID: 29967350; PMCID: PMC6553468.
Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology. 1998 Apr;114(4):842-5. doi: 10.1016/s0016-5085(98)70599-2. PMID: 9547102.
Brunt EM, Wong VW, Nobili V, Day CP, Sookoian S, Maher JJ, Bugianesi E, Sirlin CB, Neuschwander-Tetri BA, Rinella ME. Nonalcoholic fatty liver disease. Nat Rev Dis Primers. 2015 Dec 17;1:15080. doi: 10.1038/nrdp.2015.80. PMID: 27188459.
Zai W, Chen W, Liu H, Ju D. Therapeutic Opportunities of IL-22 in Non-Alcoholic Fatty Liver Disease: from Molecular Mechanisms to Clinical Applications. Biomedicines. 2021 Dec 14;9(12):1912. doi: 10.3390/biomedicines9121912. PMID: 34944732; PMCID: PMC8698419.
Zhu J, Zhou M, Zhao X, Mu M, Cheng M. Blueberry, combined with probiotics, alleviates non-alcoholic fatty liver disease via IL-22-mediated JAK1/STAT3/BAX signaling. food Funct. 2018 Dec 13;9(12):6298-6306. doi: 10.1039/c8fo01227j. PMID: 30411754.
Chen W, Zai W, Fan J, Zhang X, Zeng X, Luan J, Wang Y, Shen Y, Wang Z, Dai S, Fang S, Zhao Z, Ju D. Interleukin-22 drives a metabolic adaptive reprogramming to maintain mitochondrial fitness and treat liver injury. Theranostics. 2020 Apr 27;10(13):5879-5894. doi: 10.7150/thno.43894. PMID: 32483425. PMCID: PMC7254999.
Hu BL, Shi C, Lei RE, Lu DH, Luo W, Qin SY, Zhou Y, Jiang HX. Interleukin-22 ameliorates liver fibrosis through miR-200a/beta-catenin. Sci Rep. 2016 Nov 7;6:36436. doi: 10.1038/srep36436. PMID: 27819314; PMCID: PMC5098253.
Kong X, Feng D, Wang H, Hong F, Bertola A, Wang FS, Gao B. Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. Hepatology. 2012 Sep;56(3):1150-9. doi: 10.1002/hep.25744. Epub 2012 Jul 12. PMID: 22473749; PMCID: PMC3394879.
WANG Jianyao, LAO Jing, GUO Jingjie, et al. IL-22 mediates Notch signalling pathway to promote hepatic stellate cell apoptosis in anti-fibrotic mechanism[J]. Chinese Journal of Eugenics and Genetics, 2022, 30(03): 417-421. DOI:10.13404/j.cnki.cjbhh.20220224.019.
Xing Z, Wu Y, Liu N. IL-22 alleviates the fibrosis of hepatic stellate cells via the inactivation of NLRP3 inflammasome signaling. Exp Ther Med. 2021 Oct;22(4):1088. doi: 10.3892/etm.2021.10522. Epub 2021 Jul 30. PMID: 34447480; PMCID: PMC8355699.
Hasnain SZ, Borg DJ, Harcourt BE, Tong H, Sheng YH, Ng CP, Das I, Wang R, Chen AC, Loudovaris T, Kay TW, Thomas HE, Whitehead JP, Forbes JM, Prins JB. McGuckin MA. Glycemic control in diabetes is restored by therapeutic manipulation of cytokines that regulate beta cell stress. Nat Med. 2014 Dec;20(12) :1417-26. doi: 10.1038/nm.3705. Epub 2014 Nov 2. PMID: 25362253.
Zhang P, Liu J, Lee A, Tsaur I, Ohira M, Duong V, Vo N, Watari K, Su H, Kim JY, Gu L, Zhu M, Shalapour S, Hosseini M, Bandyopadhyay G, Zeng S, Llorente C, Zhao HN, Lamichhane S, Mohan S, Dorrestein PC, Olefsky JM, Schnabl B, Soroosh P, Karin M. IL-22 resolves MASLD via enterocyte STAT3 restoration of diet- perturbed intestinal homeostasis. Cell Metab. 2024 Oct 1;36(10):2341-2354.e6. doi: 10.1016/j.cmet. 2024. 08.012. Epub 2024 Sep 23. PMID: 39317186. PMCID: PMC11631175.
Huang Y, Yu F, Ding Y, Zhang H, Li X, Wang X, Wu X, Xu J, Wang L, Tian C, Jiang M, Zhang R, Yan C, Song Y, Huang H, Xu G, Ding Q, Ye X, Lu Y, Hu C. Hepatic IL22RA1 deficiency promotes hepatic steatosis by modulating oxysterol in the liver. deficiency promotes hepatic steatosis by modulating oxysterol in the liver. Hepatology. 2024 Jul 10. doi: 10.1097/HEP. 0000000000000998. Epub ahead of print. PMID: 38985984.
Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016 Jul;13(7):412-25. doi: 10.1038/ nrgastro.2016.85. epub 2016 Jun 8. PMID: 27273168.
Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. cell. 2014 Mar 27;157(1):121-41. doi: 10.1016/j.cell.2014.03.011. PMID. 24679531; PMCID: PMC4056765.
Zou J, Chassaing B, Singh V, Pellizzon M, Ricci M, Fythe MD, Kumar MV, Gewirtz AT. Fiber-Mediated Nourishment of Gut Microbiota Protects against Diet -Induced Obesity by Restoring IL-22-Mediated Colonic Health. Cell Host Microbe. 2018 Jan 10;23(1):41-53.e4. doi: 10.1016/j.chom.2017.11.003. epub 2017 Dec 21. PMID: 29276170; PMCID: PMC6005180.
Boniface K, Bernard FX, Garcia M, Gurney AL, Lecron JC, Morel F. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol. 2005 Mar 15;174(6):3695-702. doi: 10.4049/jimmunol.174.6.3695. PMID: 15749908.
Lai R, Xiang X, Mo R, Bao R, Wang P, Guo S, Zhao G, Gui H, Wang H, Bao S, Xie Q. Protective effect of Th22 cells and intrahepatic IL-22 in drug induced hepatocellular injury. J Hepatol. 2015 Jul;63(1):148-55. doi: 10.1016/j.jhep.2015.02.004. Epub 2015 Feb 12. PMID: 25681556.
Park O, Ki SH, Xu M, Wang H, Feng D, Tam J, Osei-Hyiaman D, Kunos G, Gao B. Biologically active, high levels of interleukin-22 inhibit hepatic gluconeogenesis but do not affect obesity and its metabolic consequences. Cell Biosci. 2015 May 30;5:25. doi: 10.1186/s13578-015-0015-0. PMID. 26064446; PMCID: PMC4462081.
Abdelnabi MN, Flores Molina M, Soucy G, Quoc-Huy Trinh V, Bédard N, Mazouz S, Jouvet N, Dion J, Tran S, Bilodeau M, Estall JL, Shoukry NH. Sex-Dependent Hepatoprotective Role of IL-22 Receptor Signaling in Non-Alcoholic Fatty Liver Disease-Related Fibrosis. Cell Mol Gastroenterol Hepatol. 2022;14(6):1269-1294. doi: 10.1016/j.jcmgh.2022.08.001. Epub 2022 Aug 13. PMID: 35970323; PMCID: PMC9596743.
Sajiir H, Ramm GA, Macdonald GA, McGuckin MA, Prins JB, Hasnain SZ. Harnessing IL-22 for metabolic health: promise and pitfalls. Trends Mol Med. 2024 Nov 21:S1471-4914(24)00283-1. doi: 10.1016/j.molmed. 2024.10.016. Epub ahead of print. PMID: 39578121.
Saxton RA, Henneberg LT, Calafiore M, Su L, Jude KM, Hanash AM, Garcia KC. The tissue protective functions of interleukin-22 can be decoupled from pro -inflammatory actions through structure-based design. Immunity. 2021 Apr 13;54(4):660-672.e9. doi: 10.1016/j.immuni.2021.03.008. PMID. 33852830; PMCID: PMC8054646.
Zai W, Chen W, Wu Z, Jin X, Fan J, Zhang X, Luan J, Tang S, Mei X, Hao Q, Liu H, Ju D. Targeted Interleukin-22 Gene Delivery in the Liver by Polymetformin and Penetratin-Based Hybrid Nanoparticles to Treat Nonalcoholic Fatty Liver Disease. ACS Appl Mater Interfaces. 2019 Feb 6; 11(5): 4842-4857. doi. 10.1021/acsami.8b19717. epub 2019 Jan 25. pmid: 30628769.
Sajiir H, Keshvari S, Wong KY, Borg DJ, Steyn FJ, Fercher C, Taylor K, Taylor B, Barnard RT, Müller A, Moniruzzaman M, Miller G, Wang R, Fotheringham A. Schreiber V, Sheng YH, Hancock JL, Loo D, Burr L, Huynh T, Lockett J, Ramm GA, Macdonald GA, Prins JB, McGuckin MA, Hasnain SZ. Liver and pancreatic- targeted interleukin-22 as a therapeutic for metabolic dysfunction-associated steatohepatitis. Nat Commun. 2024 May 29; 15(1): 4528. doi: 10.1038/ s41467-024-48317-x. PMID: 38811532; PMCID: PMC11137118.
Shen Y, Chen W, Han L, Bian Q, Fan J, Cao Z, Jin X, Ding T, Xian Z, Guo Z, Zhang W, Ju D, Mei X. VEGF-B antibody and interleukin-22 fusion protein ameliorates diabetic nephropathy through inhibiting lipid accumulation and inflammatory responses. Acta Pharm Sin B. 2021 Jan;11(1):127-142. doi: 10.1016/j. apsb.2020.07.002. epub 2020 Jul 13. PMID: 33532185; PMCID: PMC7838033.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Yuhao Pan, Zebo Yu
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
